These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 15564712)

  • 1. Plasma concentrations of cytokines and neurohumoral factors in a case of fulminant myocarditis successfully treated with intravenous immunoglobulin and percutaneous cardiopulmonary support.
    Abe S; Okura Y; Hoyano M; Kazama R; Watanabe S; Ozawa T; Saigawa T; Hayashi M; Yoshida T; Tachikawa H; Kashimura T; Suzuki K; Nagahashi M; Watanabe J; Shimada K; Hasegawa G; Kato K; Hanawa H; Kodama M; Aizawa Y
    Circ J; 2004 Dec; 68(12):1223-6. PubMed ID: 15564712
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fulminant myocarditis treated with percutaneous cardiopulmonary support system (PCPS).
    Oshima K; Kunimoto F; Hinohara H; Hayashi Y; Hirato J; Tajima Y; Kuwano H
    Ann Thorac Cardiovasc Surg; 2008 Apr; 14(2):75-80. PubMed ID: 18414343
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of acute inflammatory cardiomyopathy with intravenous immunoglobulin ameliorates left ventricular function associated with suppression of inflammatory cytokines and decreased oxidative stress.
    Kishimoto C; Shioji K; Kinoshita M; Iwase T; Tamaki S; Fujii M; Murashige A; Maruhashi H; Takeda S; Nonogi H; Hashimoto T
    Int J Cardiol; 2003 Oct; 91(2-3):173-8. PubMed ID: 14559127
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Successful high-dose intravenous immunoglobulin therapy for a patient with fulminant myocarditis.
    Kato S; Morimoto S; Hiramitsu S; Uemura A; Ohtsuki M; Kato Y; Miyagishima K; Mori N; Hishida H
    Heart Vessels; 2007 Jan; 22(1):48-51. PubMed ID: 17285446
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term prognosis of fulminant myocarditis rescued by percutaneous cardiopulmonary support device.
    Maejima Y; Yasu T; Kubo N; Kawahito K; Omura N; Katsuki T; Tsukamoto Y; Sugawara Y; Hashimoto S; Tsuruya Y; Hirahara T; Takagi Y; Kobayashi N; Funayama H; Ikeda N; Ishida T; Fujii M; Ino T; Saito M
    Circ J; 2004 Sep; 68(9):829-33. PubMed ID: 15329503
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [A case of fulminant myocarditis successfully treated by percutaneous cardiopulmonary support after 50 minuite-cardiopulmonary resuscitation].
    Asano M; Soen M; Doi Y; Kishi K; Okumura K; Mori Y; Nemoto S; Hayashi M; Umegaki O; Minami T
    Masui; 2013 Feb; 62(2):178-82. PubMed ID: 23479919
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A case of myocarditis following neonatal meningitis caused by coxsackievirus B1 in spite of intravenous immunoglobulin treatment.
    Bae EY; Lee EJ; Han SB; Lee JY; Jeong DC; Kang JH
    J Trop Pediatr; 2014 Apr; 60(2):164-7. PubMed ID: 24122863
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Successful management of a man with fulminant myocarditis using percutaneous cardiopulmonary support].
    Ohkawa M; Nishikawa K; Takazawa T; Hinohara H; Kunimoto F; Goto F
    Masui; 2005 Feb; 54(2):172-6. PubMed ID: 15747516
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A case of influenza subtype A virus-induced fulminant myocarditis: an experience of percutaneous cardio-pulmonary support (PCPS) treatment and immunohistochemical analysis.
    Miura M; Asaumi Y; Wada Y; Ogata K; Sato T; Sugawara T; Yano M; Mitsu-Oka M; Takai O; Ota K; Namiki K; Sato D; Sato E; Nagura H; Kimura T
    Tohoku J Exp Med; 2001 Sep; 195(1):11-9. PubMed ID: 11780720
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cytokine profiles in heart, spleen, and thymus during the acute stage of experimental coxsackievirus B3-induced chronic myocarditis.
    Schmidtke M; Glück B; Merkle I; Hofmann P; Stelzner A; Gemsa D
    J Med Virol; 2000 Aug; 61(4):518-26. PubMed ID: 10897072
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of naloxone, an opiate receptor antagonist, on coxsackievirus B3 myocarditis in the mouse.
    Kishimoto C; Takada H; Hiraoka Y; Shiraki K
    Cardiovasc Res; 1995 Jan; 29(1):80-4. PubMed ID: 7895243
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Successful management of fulminant myocarditis with left ventricular assist device: report of a severe case.
    Unosawa S; Hata M; Sezai A; Niino T; Yoshitake I; Shimura K; Takamori T; Minami K
    Ann Thorac Cardiovasc Surg; 2010 Aug; 16(1):48-51. PubMed ID: 20190711
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Successful immunoglobulin treatment for fulminant myocarditis and serial analysis of serum thioredoxin: a case report.
    Shioji K; Matsuura Y; Iwase T; Kitaguchi S; Nakamura H; Yodoi J; Hashimoto T; Kawai C; Kishimoto C
    Circ J; 2002 Oct; 66(10):977-80. PubMed ID: 12381097
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tanshinone IIA Ameliorate Coxsackie Virus B3-Induced Viral Myocarditis through the Inhibition of Inflammation and Modulation T Helper 1/T Helper 2 Balance in Mice.
    Guo G; Zhao Q; Wang Q; Li E
    Pharmacology; 2019; 103(3-4):136-142. PubMed ID: 30602153
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fasudil exerts a cardio-protective effect on mice with coxsackievirus B3-induced acute viral myocarditis.
    Dai K; Wang Y; Tai S; Ni H; Lian H; Yu Y; Liao W; Zheng C; Chen Q; Kuver A; Li J
    Cardiovasc Ther; 2018 Dec; 36(6):e12477. PubMed ID: 30380183
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pathogenesis of coxsackievirus B3-induced myocarditis: role of macrophage migration inhibitory factor.
    Yu XH; Li SJ; Chen RZ; Yang YZ; Zhang P
    Chin Med J (Engl); 2012 Jan; 125(1):50-5. PubMed ID: 22340465
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TNFR-Fc fusion protein expressed by in vivo electroporation improves survival rates and myocardial injury in coxsackievirus induced murine myocarditis.
    Kim JM; Lim BK; Ho SH; Yun SH; Shin JO; Park EM; Kim DK; Kim S; Jeon ES
    Biochem Biophys Res Commun; 2006 Jun; 344(3):765-71. PubMed ID: 16631119
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The therapeutic effect of intravenous immunoglobulins and vitamin C on the progression of experimental autoimmune myocarditis in the mouse.
    Gong F; Hu Y; Chen L; Gu W
    Med Sci Monit; 2007 Nov; 13(11):BR240-246. PubMed ID: 17968290
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Wnt11 gene therapy with adeno-associated virus 9 improves the survival of mice with myocarditis induced by coxsackievirus B3 through the suppression of the inflammatory reaction.
    Aoyama Y; Kobayashi K; Morishita Y; Maeda K; Murohara T
    J Mol Cell Cardiol; 2015 Jul; 84():45-51. PubMed ID: 25886696
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vivo delivery of interleukin-35 relieves coxsackievirus-B3-induced viral myocarditis by inhibiting Th17 cells.
    Hu Y; Dong C; Yue Y; Xiong S
    Arch Virol; 2014 Sep; 159(9):2411-9. PubMed ID: 24788848
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.